Synthetic strategies for oseltamivir phosphate

European Journal of Organic Chemistry

Volumn , Issue 11, 2008, Pages 1839-1850

  Shibasaki, Masakatsu ^a   Kanai, Motomu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Analogue synthesis; Asymmetric catalysis; Influenza; Oseltamivir phosphate; Process chemistry; Tamiflu

Indexed keywords

EID: 46849088854     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200800033     Document Type: Short Survey

References (56)

1. a) P. M. Colman, J. N. Varghese, W. G. Laver, Nature 1983, 303, 41-44;
2. b) J. N. Varghese, J. L. McKimm-Breschkin, J. B. Caldwell, Proteins Struct. Funct. Genet. 1992, 14, 327-332.
3. M. von Itzstein, W.-Y. Wu, G. B. Kok, M. S. Pegg, J. C. Dyason, B. Jin, T. V. Phan, M. L. Smythe, H. F. White, S. W. Oliver, P. M. Colman, J. N. Varghese, D. M. Ryan, J. M. Woods, R. C. Bethell, V. J. Hotham, J. M. Cameron, C. R. Penn, Nature 1993, 363, 418-423.
4. a) C. U. Kim, W. Lew, M. A. Williams, H. Liu, L. Zhang, S. Swaminathan, N. Bischofberger, M. S. Chen, D. B. Mendel, C. Y. Tai, W. G. Laver, R. C. Stevens, J. Am. Chem. Soc. 1997, 119, 681-690;
5. b) For a recent review on the synthesis of 6, see: V. Farina, J. D. Brown, Angew. Chem. Int. Ed. 2006, 45, 7330-7334.
6. C. U. Kim, W. Lew, M. A. Williams, H. Wu, L. Zhang, X. Chen, P. A. Escarpe, D. B. Mendel, W. G. Laver, R. C. Stevens, J. Med. Chem. 1998, 41, 2451-2460.
7. K. M. Draths, D. R. Knop, J. W. Frost, J. Am. Chem. Soc. 1999, 121, 1603-1604.
8. a) J. C. Rohloff, K. M. Kent, M. J. Postich, M. W. Becker, H. H. Chapman, D. E. Kelly, W. Lew, M. S. Louie, L. R. McGee, E. J. Prisbe, L. M. Schultze, R. H. Yu, L. Zhang, J. Org. Chem. 1998, 63, 4545-4550;
9. b) M. Federspiel, R. Fischer, M. Hennig, H.-J. Mair, T. Oberhauser, G. Rimmler, T. Albiez, J. Bruhin, H. Estermann, C. Gandert, V. Göckel, S. Götzö, U. Hoffmann, G. Huber, G. Janatsch, S. Lauper, O. Röckel-Stäbler, R. Trussardi, A. G. Zwahlen, Org. Process Res. Dev. 1999, 3, 266-274;
10. c) S. Abrecht, P. Harrington, H. Iding, M. Karpf, R. Trussardi, B. Wirz, U. Zutter, Chimia 2004, 58, 621-629;
11. d) S. Abrecht, M. C. Federspiel, H. Estermann, R. Fischer, M. Karpf, H.-J. Mair, T. Oberhauser, G. Rimmler, R. Trussardi, U. Zutter, Chimia 2007, 61, 93-99.
12. a) P. J. Harrington, J. D. Brown, T. Foderaro, R. C. Hughes, Org. Process Res. Dev. 2004, 8, 86-91;
13. b) For an azide-free route using allylamine, see: M. Karpf, R. Trussardi, J. Org. Chem. 2001, 66, 2044-2051.
14. T. Shioiri, K. Ninomiya, S. Yamada, J. Am. Chem. Soc. 1972, 94, 6203-6205.
15. Y.-Y. Yeung, S. Hong, E. J. Corey, J. Am. Chem. Soc. 2006, 128, 6310-6311.
16. D. H. Ryu, E. J. Corey, J. Am. Chem. Soc. 2003, 125, 6388-6390.
17. The conversion from 53 to 56 is an improved method in relation to the original report in ref. [9], see: Y.-Y. Yeung, E. J. Corey, Tetrahedron Lett. 2007, 48, 7567-7570.
18. Y.-Y. Yeung, X. Gao, E. J. Corey, J. Am. Chem. Soc. 2006, 128, 9644-9645.
19. Y. Fukuta, T. Mita, N. Fukuda, M. Kanai, M. Shibasaki, J. Am. Chem. Soc. 2006, 128, 6312-6313.
20. For other examples of catalytic asymmetric aziridine-opening reactions with nitrogen nucleophiles, see: a) Z. Li, M. Fernández, E. N. Jacobsen, Org. Lett. 1999, 1, 1611-1613;
21. b) K. Arai, S. Lucarini, M. M. Salter, K. Ohta, Y. Yamashita, S. Kobayashi, J. Am. Chem. Soc. 2007, 129, 8103-8111.
22. For reviews of the utility of asymmetric catalysts derived from ligand 67, see: a) M. Kanai, N. Kato, E. Ichikawa, M. Shibasaki, Synlett 2005, 1491-1508;
23. b) M. Shibasaki, M. Kanai, S. Matsunaga, Aldrichimica Acta 2006, 39, 31-39;
24. c) M. Shibasaki, M. Kanai, Org. Biomol. Chem. 2007, 5, 2027-2039.
25. N. Kato, T. Mita, M. Kanai, B. Therrien, M. Kawano, K. Yamaguchi, H. Danjo, Y. Sei, A. Sato, A. Furusho, M. Shibasaki, J. Am. Chem. Soc. 2006, 128, 6768-6769.
26. K. Yabu, S. Masumoto, S. Yamasaki, Y. Hamashima, M. Kanai, W. Du, D. P. Curran, M. Shibasaki, J. Am. Chem. Soc. 2001, 123, 9908-9909.
27. K. B. Wilberg, S. D. Nielsen, J. Org. Chem. 1964, 29, 3353-3361.
28. Y. Tanaka, M. Kanai, M. Shibasaki, manuscript in preparation.
29. M. Ho, J. K. K. Chung, N. Tang, Tetrahedron Lett. 1993, 34, 6513-6516.
30. The conversion from 74 to 6 is an improved method in relation to the original report in ref.[13] See: M. Morita, T. Sone, K. Yamatsugu, Y. Sohtome, S. Matsunaga, M. Kanai, Y. Watanabe, M. Shibasaki, Bioorg. Med. Chem. Lett. 2008, 18, 600-602.
31. T. Mita, N. Fukuda, F. X. Roca, M. Kanai, M. Shibasaki, Org. Lett. 2007, 9, 259-262.
32. N. Shangguan, S. Katsukojvala, R. Greenberg, L. J. Williams, J. Am. Chem. Soc. 2003, 125, 7754-7755.
33. a) S. Yamada, Y. Kasai, T. Shioiri, Tetrahedron Lett. 1973, 14, 1595-1598;
34. b) S. Harusawa, R. Yoneda, T. Kurihara, Y. Hamada, T. Shioiri, Tetrahedron Lett. 1984, 25, 427-428.
35. a) P. A. Bartlett, L. A. MacQuaid, J. Am. Chem. Soc. 1984, 106, 7854-7860;
36. b) T. Kurihara, M. Miki, R. Yoneda, S. Harusawa, Chem. Pharm. Bull. 1986, 34, 2747-2753.
37. K. Yamatsugu, S. Kamijo, Y. Suto, M. Kanai, M. Shibasaki, Tetrahedron Lett. 2007, 48, 1403-1406.
38. J. D. Albright, L. Goldman, J. Am. Chem. Soc. 1967, 89, 2416-2423.
39. For references relating to the effects of oseltamivir on the nervous system, see: a) Y. Izumi, K. Tokuda, K. A. O'Dell, C. F. Zorumski, T. Narahashi, Neurosci. Lett. 2007, 426, 54-58;
40. b) K. Ishii, H. Hamamoto, T. Sasaki, Y. Ikegaya, K. Yamatsugu, M. Kanai, M. Shibasaki, K. Sekimizu, Drug Discoveries & Therapeutics 2008, 2, 164-174;
41. c) K. Morimoto, M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, T. Ogihara, Drug Metab. Dispos. 2008, 36, 6-9;
42. d) A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, Y. Sugiyama, Drug Metab. Dispos. 2008, 36; doi:10.1124/dmd.107.018556;
43. e) A. Usami, T. Sasaki, N. Satoh, T. Akiba, S. Yokoshima, T. Fukuyama, K. Yamatsugu, M. Kanai, M. Shibasaki, N. Matsuki, Y. Ikegaya, J. Pharmacol. Sci., in press.
44. For recent reviews, see: a) K. A. Wood, P. J. Hoskin, M. I. Saunders, Clin. Oncol. 2007, 19, 237-255;
45. b) J. S. Welsh, Am. J. Clin. Oncol. 2007, 30, 437-439.
46. X. Cong, Z.-J. Yao, J. Org. Chem. 2006, 71, 5635-5638.
47. X. Cong, Q.-J. Liao, Z.-J. Yao, J. Org. Chem. 2004, 69, 5314-5321.
48. Our studies indicated that the introduction of a 3-pentyl group at the C-3 oxygen in compounds related to 100 (containing C-4-acetamide and C-1-ester functions) was impossible (Y. Kimura, K. Yamatsugu, M. Kanai, M. Shibasaki, unpublished results).
49. N. Satoh, T. Akiba, S. Yokoshima, T. Fukuyama, Angew. Chem. Int. Ed. 2007, 46, 5734-5736.
50. a) K. A. Ahrendt, C. J. Borths, D. W. C. MacMillan, J. Am. Chem. Soc. 2000, 122, 4243-4244;
51. b) G. Lelais, D. W. C. MacMillan, Aldrichimica Acta 2006, 39, 79-87.
52. R. M. Moriarty, C. J. Chany II, R. K. Vaid, O. Prakash, S. M. Tuladhar, J. Org. Chem. 1993, 58, 2478-2482.
53. K. M. Bromfield, H. Gradén, D. P. Hagberg, T. Olsson, N. Kann, Chem. Commun. 2007, 3183-3185.
54. F. Bohlmann, C. Zdero, Chem. Ber. 1973, 106, 3779-3787.
55. J.-J. Shie, J.-M. Fang, S.-Y. Wang, K.-C. Tsai, Y.-S. E. Cheng, A.-S. Yang, S.-C. Hsiao, C.-Y. Su, C.-H. Wong, J. Am. Chem. Soc. 2007, 129, 11892-11893.
56. K. D. Stigers, R. Mar-Tang, P. A. Bartlett, J. Org. Chem. 1999, 64, 8409-8410.